Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.88
WX's Cash to Debt is ranked lower than
55% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. WX: 1.88 )
Ranked among companies with meaningful Cash to Debt only.
WX' s Cash to Debt Range Over the Past 10 Years
Min: 0.33  Med: 3.27 Max: N/A
Current: 1.88
Equity to Asset 0.67
WX's Equity to Asset is ranked higher than
61% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. WX: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
WX' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.72 Max: 0.8
Current: 0.67
-0.32
0.8
Interest Coverage N/A
WX's Interest Coverage is ranked higher than
76% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. WX: N/A )
Ranked among companies with meaningful Interest Coverage only.
WX' s Interest Coverage Range Over the Past 10 Years
Min: 6.71  Med: 48.81 Max: 163.99
Current: N/A
6.71
163.99
F-Score: 2
Z-Score: 5.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.85
WX's Operating margin (%) is ranked higher than
72% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. WX: 10.85 )
Ranked among companies with meaningful Operating margin (%) only.
WX' s Operating margin (%) Range Over the Past 10 Years
Min: -8.26  Med: 18.76 Max: 25.87
Current: 10.85
-8.26
25.87
Net-margin (%) 10.89
WX's Net-margin (%) is ranked higher than
79% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. WX: 10.89 )
Ranked among companies with meaningful Net-margin (%) only.
WX' s Net-margin (%) Range Over the Past 10 Years
Min: -25.33  Med: 18.86 Max: 27.18
Current: 10.89
-25.33
27.18
ROE (%) 10.40
WX's ROE (%) is ranked higher than
75% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.56 vs. WX: 10.40 )
Ranked among companies with meaningful ROE (%) only.
WX' s ROE (%) Range Over the Past 10 Years
Min: -688.03  Med: 16.72 Max: 27.07
Current: 10.4
-688.03
27.07
ROA (%) 6.83
WX's ROA (%) is ranked higher than
78% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. WX: 6.83 )
Ranked among companies with meaningful ROA (%) only.
WX' s ROA (%) Range Over the Past 10 Years
Min: -18.88  Med: 13.97 Max: 29.99
Current: 6.83
-18.88
29.99
ROC (Joel Greenblatt) (%) 26.22
WX's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. WX: 26.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
WX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -14.87  Med: 35.88 Max: 71.72
Current: 26.22
-14.87
71.72
Revenue Growth (3Y)(%) 20.10
WX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. WX: 20.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
WX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.7  Med: 23.30 Max: 157.5
Current: 20.1
10.7
157.5
EBITDA Growth (3Y)(%) 13.60
WX's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. WX: 13.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
WX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 21.10 Max: 102.6
Current: 13.6
0
102.6
EPS Growth (3Y)(%) 13.20
WX's EPS Growth (3Y)(%) is ranked higher than
76% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. WX: 13.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
WX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 15.70 Max: 330.9
Current: 13.2
0
330.9
» WX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

WX Guru Trades in Q1 2015

Matthews Pacific Tiger Fund 2,243,158 sh (New)
Ron Baron 341,500 sh (+35.79%)
Mario Gabelli 57,200 sh (unchged)
Sarah Ketterer 105,600 sh (-41.56%)
Jim Simons 55,400 sh (-53.52%)
Columbia Wanger 1,147,000 sh (-65.60%)
» More
Q2 2015

WX Guru Trades in Q2 2015

Value Partners 209,522 sh (New)
First Eagle Investment 10,000 sh (New)
Matthews Pacific Tiger Fund 2,243,158 sh (unchged)
Ron Baron 341,500 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 54,200 sh (-5.24%)
Columbia Wanger 1,013,906 sh (-11.60%)
Sarah Ketterer 61,900 sh (-41.38%)
» More
Q3 2015

WX Guru Trades in Q3 2015

John Burbank 8,151 sh (New)
Mario Gabelli 61,300 sh (+13.10%)
Sarah Ketterer 65,400 sh (+5.65%)
Ron Baron 341,500 sh (unchged)
Matthews Pacific Tiger Fund 2,243,158 sh (unchged)
First Eagle Investment Sold Out
Columbia Wanger 578,000 sh (-42.99%)
» More
Q4 2015

WX Guru Trades in Q4 2015

Matthews Pacific Tiger Fund Sold Out
Ron Baron Sold Out
Sarah Ketterer Sold Out
John Burbank Sold Out
Columbia Wanger Sold Out
Mario Gabelli Sold Out
Value Partners Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with WX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:DSRLF, NAS:PRXL, OTCPK:SWTUY, OTCPK:CZMWF, NYSE:ALR, NAS:BRKR, NAS:ICLR, NYSE:CRL, NAS:VWR, NAS:PRAH, NYSE:BIO, NAS:CPHD, NAS:MYGN, NAS:INCR, NAS:NEOG, NAS:QGEN, OTCPK:BMXMF, NAS:KANG, NAS:EXAS, NAS:AFFX » details
Traded in other countries:3W11.Germany,


WuXi PharmaTech (Cayman) Inc was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safe

Ratios

vs
industry
vs
history
P/E(ttm) 38.57
WX's P/E(ttm) is ranked lower than
63% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.99 vs. WX: 38.57 )
Ranked among companies with meaningful P/E(ttm) only.
WX' s P/E(ttm) Range Over the Past 10 Years
Min: 6.67  Med: 18.83 Max: 103.94
Current: 38.57
6.67
103.94
Forward P/E 23.70
WX's Forward P/E is ranked lower than
60% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. WX: 23.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 38.90
WX's PE(NRI) is ranked lower than
65% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.19 vs. WX: 38.90 )
Ranked among companies with meaningful PE(NRI) only.
WX' s PE(NRI) Range Over the Past 10 Years
Min: 6.62  Med: 17.91 Max: 102.94
Current: 38.9
6.62
102.94
Price/Owner Earnings (ttm) 44.22
WX's Price/Owner Earnings (ttm) is ranked lower than
68% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.99 vs. WX: 44.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
WX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.42  Med: 14.47 Max: 26.27
Current: 44.22
9.42
26.27
P/B 3.61
WX's P/B is ranked lower than
57% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. WX: 3.61 )
Ranked among companies with meaningful P/B only.
WX' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 3.17 Max: 10.64
Current: 3.61
1.11
10.64
P/S 4.26
WX's P/S is ranked lower than
61% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. WX: 4.26 )
Ranked among companies with meaningful P/S only.
WX' s P/S Range Over the Past 10 Years
Min: 0.79  Med: 3.58 Max: 11.05
Current: 4.26
0.79
11.05
EV-to-EBIT 26.00
WX's EV-to-EBIT is ranked lower than
69% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.18 vs. WX: 26.00 )
Ranked among companies with meaningful EV-to-EBIT only.
WX' s EV-to-EBIT Range Over the Past 10 Years
Min: -155.4  Med: 14.80 Max: 118.4
Current: 26
-155.4
118.4
EV-to-EBITDA 26.00
WX's EV-to-EBITDA is ranked lower than
80% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.58 vs. WX: 26.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
WX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.4  Med: 14.80 Max: 113.9
Current: 26
-155.4
113.9
PEG 2.36
WX's PEG is ranked higher than
59% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. WX: 2.36 )
Ranked among companies with meaningful PEG only.
WX' s PEG Range Over the Past 10 Years
Min: 2.33  Med: 3.62 Max: 4.41
Current: 2.36
2.33
4.41
Shiller P/E 58.22
WX's Shiller P/E is ranked lower than
77% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. WX: 58.22 )
Ranked among companies with meaningful Shiller P/E only.
WX' s Shiller P/E Range Over the Past 10 Years
Min: 43.31  Med: 53.85 Max: 58.68
Current: 58.22
43.31
58.68
Current Ratio 2.36
WX's Current Ratio is ranked lower than
54% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.85 vs. WX: 2.36 )
Ranked among companies with meaningful Current Ratio only.
WX' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.62 Max: 5.75
Current: 2.36
0.79
5.75
Quick Ratio 2.14
WX's Quick Ratio is ranked lower than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. WX: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
WX' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 2.32 Max: 5.45
Current: 2.14
0.6
5.45
Days Inventory 38.78
WX's Days Inventory is ranked higher than
71% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. WX: 38.78 )
Ranked among companies with meaningful Days Inventory only.
WX' s Days Inventory Range Over the Past 10 Years
Min: 23.55  Med: 43.02 Max: 66.63
Current: 38.78
23.55
66.63
Days Sales Outstanding 90.83
WX's Days Sales Outstanding is ranked lower than
74% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. WX: 90.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
WX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.86  Med: 63.76 Max: 88.2
Current: 90.83
47.86
88.2
Days Payable 45.69
WX's Days Payable is ranked lower than
59% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. WX: 45.69 )
Ranked among companies with meaningful Days Payable only.
WX' s Days Payable Range Over the Past 10 Years
Min: 25.14  Med: 34.88 Max: 94.86
Current: 45.69
25.14
94.86

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.00
WX's Price/Net Current Asset Value is ranked lower than
71% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. WX: 15.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.31  Med: 8.44 Max: 61.52
Current: 15
4.31
61.52
Price/Tangible Book 4.35
WX's Price/Tangible Book is ranked higher than
53% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.69 vs. WX: 4.35 )
Ranked among companies with meaningful Price/Tangible Book only.
WX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.45  Med: 3.51 Max: 9.1
Current: 4.35
1.45
9.1
Price/Projected FCF 4.60
WX's Price/Projected FCF is ranked lower than
78% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. WX: 4.60 )
Ranked among companies with meaningful Price/Projected FCF only.
WX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.98  Med: 3.61 Max: 4.82
Current: 4.6
1.98
4.82
Price/Median PS Value 1.19
WX's Price/Median PS Value is ranked lower than
70% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. WX: 1.19 )
Ranked among companies with meaningful Price/Median PS Value only.
WX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 1.01 Max: 2.53
Current: 1.19
0.27
2.53
Price/Peter Lynch Fair Value 3.95
WX's Price/Peter Lynch Fair Value is ranked lower than
88% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. WX: 3.95 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.25  Med: 0.57 Max: 4.32
Current: 3.95
0.25
4.32
Price/Graham Number 2.74
WX's Price/Graham Number is ranked higher than
58% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.18 vs. WX: 2.74 )
Ranked among companies with meaningful Price/Graham Number only.
WX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.89  Med: 1.61 Max: 5.49
Current: 2.74
0.89
5.49
Earnings Yield (Greenblatt) (%) 3.80
WX's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. WX: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 6.40 Max: 16.7
Current: 3.8
0.8
16.7
Forward Rate of Return (Yacktman) (%) 9.84
WX's Forward Rate of Return (Yacktman) (%) is ranked higher than
51% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.84 vs. WX: 9.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.40 Max: 12.2
Current: 9.84
0.2
12.2

More Statistics

Revenue (TTM) (Mil) $778.5
EPS (TTM) $ 1.19
Short Percentage of Float0.35%
52-Week Range $32.50 - 46.14
Shares Outstanding (Mil)71.00

Analyst Estimate

Dec15
Revenue (Mil $)
EPS ($) 14.40
EPS w/o NRI ($) 14.40
EPS Growth Rate
(3Y to 5Y Estimate)
13.35%
» More Articles for WX

Headlines

Articles On GuruFocus.com
Matthews Pacific Tiger Fund Adds 2 New Stocks to Portfolio May 05 2015 
Baron Funds Comments on WuXi PharmaTech Feb 24 2014 
Columbia Management's Top 5 New Buys Amid Buoyant Outlook Aug 12 2013 
Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
Stocks That Julian Robertson Keeps Buying Dec 23 2011 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 

More From Other Websites
LabNetwork Forges eCommerce Alliances with Leading Chemical Providers Apr 27 2016
LabNetwork Forges eCommerce Alliances with Leading Chemical Providers Apr 27 2016
AstraZeneca Invests in China, To Buy Respiratory Business Dec 17 2015
WuXi and AstraZeneca Form Strategic Alliance to Expedite Development of AstraZeneca's Innovative... Dec 16 2015
WuXi PharmaTech Presents 2015 Life Science and Chemistry Awards Dec 13 2015
WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction Dec 10 2015
WuXi PharmaTech (Cayman) Inc. Announces Completion of Going Private Transaction Dec 10 2015
WUXI PHARMATECH (CAYMAN) INC. Financials Dec 08 2015
WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China Dec 07 2015
Dr. Ge Li Receives Executive of the Year Award from SCRIP Dec 07 2015
Is Royal Gold, Inc USA) (RGLD) A Good Stock To Buy? Dec 02 2015
WuXi PharmaTech Announces Shareholders' Approval of Merger Agreement Nov 24 2015
Do Hedge Funds Love WuXi PharmaTech (Cayman) Inc. (ADR) (WX)? Nov 24 2015
The State Of Chinese Company Take-Private Offers: A Look At WuXi PharmaTech Nov 19 2015
Wuxi PharmaTech (Cayman) Inc. Earnings Q3, 2015 Nov 18 2015
Genomics England Contracts With WuXi NextCODE as Clinical Interpretation Partner in Both Rare... Nov 12 2015
Genomics England Contracts with WuXi NextCODE as Clinical Interpretation Partner in both Rare... Nov 12 2015
Lion Biotechnologies Announces Agreement with WuXi AppTec to Increase TIL Manufacturing Capacity Nov 11 2015
ISS and Glass Lewis Recommend that WuXi PharmaTech Shareholders Vote "FOR" the Proposed... Nov 11 2015
ISS and Glass Lewis Recommend that WuXi PharmaTech Shareholders Vote "FOR" the Proposed... Nov 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)